This research identifies CRTAM as a critical immune-related adverse event (irAE) checkpoint that governs the balance between immunotherapy efficacy and side effects. By analyzing patient data and mouse models, the authors discovered that CRTAM+ T cells drive inflammatory toxicity in normal organs like the lungs and colon without significantly affecting antitumor immunity. This specific toxicity occurs because CRTAM interacts with CADM1, a protein found more abundantly in healthy epithelial tissues than in malignant tumors. Experiments showed that inhibiting or deleting CRTAM reduces severe inflammation and tissue damage while preserving the "hot" tumor environment necessary for cancer treatment. Furthermore, the study suggests that the CRTAM–type 3 immune axis can serve as a biomarker to monitor patients for potential side effects. Ultimately, targeting CRTAM offers a promising strategy to decouple treatment toxicity from efficacy, allowing for safer and more effective cancer immunotherapy.

References:

• Ma S C, Rong Z X, Xu Z P, et al. CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off[J]. Nature Cancer, 2026: 1-17.